Primary Sclerosing Cholangitis - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Pipeline Review, H2 2016’, provides an overview of the Primary Sclerosing Cholangitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis
- The report reviews pipeline therapeutics for Primary Sclerosing Cholangitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Primary Sclerosing Cholangitis therapeutics and enlists all their major and minor projects
- The report assesses Primary Sclerosing Cholangitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Primary Sclerosing Cholangitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Primary Sclerosing Cholangitis Overview 7
Therapeutics Development 8
Pipeline Products for Primary Sclerosing Cholangitis - Overview 8
Primary Sclerosing Cholangitis - Therapeutics under Development by Companies 9
Primary Sclerosing Cholangitis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Primary Sclerosing Cholangitis - Products under Development by Companies 14
Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development 15
Biotie Therapies Corp. 15
ChemoCentryx, Inc. 16
Dr. Falk Pharma GmbH 17
Genextra S.p.a. 18
Gilead Sciences, Inc. 19
iCo Therapeutics Inc. 20
NGM Biopharmaceuticals, Inc. 21
Sancilio & Company, Inc. 22
Shire Plc 23
Takeda Pharmaceutical Company Limited 24
TGV-Laboratories 25
Tobira Therapeutics, Inc. 26
Primary Sclerosing Cholangitis - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
bertilimumab - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
BTT-1023 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
CCX-507 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
cenicriviroc mesylate - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Hep-114 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
maralixibat chloride - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
NGM-282 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
norursodeoxycholic acid - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
obeticholic acid - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
SC-404 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
simtuzumab - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Stem Cell Therapy for Primary Sclerosing Cholangitis - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
vedolizumab - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Primary Sclerosing Cholangitis - Dormant Projects 76
Primary Sclerosing Cholangitis - Product Development Milestones 77
Featured News & Press Releases 77
Jun 07, 2016: Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases 77
Apr 16, 2016: Investigational treatment provides hope for some chronic liver disease sufferers 77
Apr 16, 2016: Gilead Presents New Data on Simtuzumab at The International Liver Congress 2016 78
Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis 78
Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015 79
Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting 80
Mar 31, 2015: Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis 82
Feb 17, 2015: BTT1023 receives positive opinion for Orphan Drug Designation from COMP 83
Jul 24, 2014: Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding 83
Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases 84
Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases 84
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87
List Of Tables
List of Tables
Number of Products under Development for Primary Sclerosing Cholangitis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Comparative Analysis by Unknown Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Primary Sclerosing Cholangitis - Pipeline by Biotie Therapies Corp., H2 2016 15
Primary Sclerosing Cholangitis - Pipeline by ChemoCentryx, Inc., H2 2016 16
Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016 17
Primary Sclerosing Cholangitis - Pipeline by Genextra S.p.a., H2 2016 18
Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences, Inc., H2 2016 19
Primary Sclerosing Cholangitis - Pipeline by iCo Therapeutics Inc., H2 2016 20
Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016 21
Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company, Inc., H2 2016 22
Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H2 2016 23
Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 24
Primary Sclerosing Cholangitis - Pipeline by TGV-Laboratories, H2 2016 25
Primary Sclerosing Cholangitis - Pipeline by Tobira Therapeutics, Inc., H2 2016 26
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Stage and Target, H2 2016 29
Number of Products by Stage and Mechanism of Action, H2 2016 31
Number of Products by Stage and Route of Administration, H2 2016 33
Number of Products by Stage and Molecule Type, H2 2016 35
Primary Sclerosing Cholangitis - Dormant Projects, H2 2016 76
Lisst Of Figures
List of Figures
Number of Products under Development for Primary Sclerosing Cholangitis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 27
Number of Products by Top 10 Targets, H2 2016 28
Number of Products by Stage and Top 10 Targets, H2 2016 28
Number of Products by Top 10 Mechanism of Actions, H2 2016 30
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 30
Number of Products by Routes of Administration, H2 2016 32
Number of Products by Stage and Routes of Administration, H2 2016 32
Number of Products by Molecule Types, H2 2016 34
Number of Products by Stage and Molecule Types, H2 2016 34
